摘要
目的分析各期小儿血管瘤CXCL12/CXCR4及VEGF的表达变化规律,以期为临床诊断及治疗提供参考。方法收集经病理学诊断为小儿血管瘤的患者临床资料共210例,其中增生期血管瘤患者90例,消退期血管瘤患者120例。以海南医学院第一附属医院儿科同期健康体检者60例为对照组。采用定量PCR及酶联免疫吸附测定法分析各组血清中CXCL12/CXCR4及VEGF的表达。结果小儿血管瘤组CXCL12/CXCR4和VEGF及其受体m RNA及蛋白水平明显高于对照组(P<0.05),且增生期血管瘤患儿水平显著高于消退期血管瘤患儿(P<0.05)。结论 CXCL12/CXCR4及VEGF在小儿血管瘤增生期及消退期表达有明显差异,提示其参与了小儿血管瘤病理演变。
Objective The present research tried to explore the role of CXCL12/CXCR4 and VEGF in the development of children hemangioma.Methods 210 cases of children hemangioma patients in our department were enrolled in this part.The expression of CXCL12/CXCR4 and VEGF were assayed in patients with different stages of children hemangioma.60 healthy subjects were taken as control group at the same period.Results The results showed that the mRNA and protein levels of CXCL12/CXCR4 and VEGF were higher in children hemangioma patients than in control group(P<0.05).At the same time,the mRNA and protein levels of CXCL12/CXCR4 and VEGF were higher in proliferating stage than in involuting stage patients,with a statistical difference(P<0.05).Conclusion CXCL12/CXCR4 and VEGF levels have a close relationship with the pathological process of children hemangioma.
作者
李立佳
何秀娟
符梅竹
黄惠敏
谢海清
郑诗华
张晓钿
LI Lijia;HE Xiujuan;FU Meizhu;HUANG Huimin;XIE Haiqing;ZHENG Shihua;ZHANG Xiaodian(Pediatric Department,the First Affiliated Hospital of Hainan Medical College,Haikou,Hainan,571199,China;Pathology Department,Hainan Cancer Hospital,Haikou,Hainan,571199,China;Drug Safety Evaluation Research Center,Hainan Medical College,Haikou,Hainan,571199,China)
出处
《肿瘤药学》
CAS
2018年第3期420-423,共4页
Anti-Tumor Pharmacy
基金
海南省高等学校科学研究项目(Hnky2017-33)
海南省卫生计生行业科研项目(16A200012
1601032034A2002)
关键词
血管瘤
增生期
消退期
酶联免疫吸附法
Children hemangioma
Proliferating stage
Involuting stage
ELISA
